JPMorgan Chase Raises Pacira Pharmaceuticals (PCRX) Price Target to $43.00

Pacira Pharmaceuticals (NASDAQ:PCRX) had its target price upped by stock analysts at JPMorgan Chase from $40.00 to $43.00 in a research note issued to investors on Tuesday. The firm presently has a “neutral” rating on the stock. JPMorgan Chase’s price target would indicate a potential upside of 28.55% from the company’s current price.

PCRX has been the subject of a number of other research reports. Oppenheimer reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, March 1st. Royal Bank of Canada set a $44.00 price target on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 1st. ValuEngine upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday. BidaskClub cut shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. Finally, Wedbush reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $44.35.

Shares of NASDAQ PCRX traded down $1.10 during mid-day trading on Tuesday, reaching $33.45. The company had a trading volume of 1,628,686 shares, compared to its average volume of 1,212,933. The company has a quick ratio of 6.22, a current ratio of 6.96 and a debt-to-equity ratio of 0.99. Pacira Pharmaceuticals has a 52-week low of $26.95 and a 52-week high of $52.47.



Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.46. The firm had revenue of $79.08 million for the quarter, compared to the consensus estimate of $79.06 million. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The company’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm posted $0.09 EPS. equities analysts anticipate that Pacira Pharmaceuticals will post -0.51 EPS for the current year.

Large investors have recently bought and sold shares of the business. First Republic Investment Management Inc. purchased a new position in Pacira Pharmaceuticals during the 4th quarter valued at about $201,000. Bouchey Financial Group Ltd purchased a new position in Pacira Pharmaceuticals during the 4th quarter valued at about $205,000. Twin Focus Capital Partners LLC purchased a new position in Pacira Pharmaceuticals during the 4th quarter valued at about $206,000. Redmile Group LLC purchased a new position in Pacira Pharmaceuticals during the 4th quarter valued at about $237,000. Finally, Fisher Asset Management LLC purchased a new position in Pacira Pharmaceuticals during the 4th quarter valued at about $241,000.

TRADEMARK VIOLATION WARNING: This report was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://dakotafinancialnews.com/2018/04/12/pacira-pharmaceuticals-pcrx-pt-raised-to-43-00-at-jpmorgan-chase.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply